title: Ipilimumab-Induced Neutropenia in Melanoma.
abstract: Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related. Severe hematological toxicity is rare. We report a case of severe neutropenia following ipilimumab therapy that fully resolved after the administration of prednisone, cyclosporine, and anti-thymocyte globulin therapies.
authors: University of Rochester Medical Center, Rochester, NY, USA.
authors: Makiko
authors: M
authors: Ban-Hoefen
authors: University of Rochester Medical Center, Rochester, NY, USA.
authors: Richard
authors: R
authors: Burack
authors: University of Rochester Medical Center, Rochester, NY, USA.
authors: Lynn
authors: L
authors: Sievert
authors: University of Rochester Medical Center, Rochester, NY, USA.
authors: Deepak
authors: D
authors: Sahasrabudhe
keywords: checkpoint inhibitors; immune-mediated; ipilimumab; melanoma; neutropenia